| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6170429 | The Breast | 2011 | 7 Pages |
Abstract
Our data do not support a correlation between topoisomerase II-α expression in breast cancer patients and improved clinical benefit with anthracycline therapy. However, they do suggest that tumors overexpressing topoisomerase II-α may experience better clinical benefit with higher anthracycline dose intensity.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Henry L. Gómez, Joseph A. Pinto, Mivael Olivera, Tatiana Vidaurre, Franco D. Doimi, Carlos E. Vigil, Raúl G. Velarde, Julio E. Abugattas, Edith Alarcón, Carlos S. Vallejos,